

REMARKS

Upon entry of the present Amendment, claims 36, 37, 39, 40, 42-44, 47, 48, 50, 53, 57, 69, 71-77 and 79 will be pending. Claims 1-35, 38, 41, 45, 46, 49, 51, 52, 54-56, 58-68, 70 and 78 are withdrawn from consideration and/or canceled. Applicant reserves the rights to pursue the withdrawn and/or canceled subject matter in a subsequent application. Support for amended claim 44 for reciting "an enzyme selected from the group consisting of *Vibrio cholera* neuraminidase (VCN), Papain, β -Gal and ConA, a non-virulent Newcastle virus, and a polysaccharide selected from the group consisting of glucomannan, β -(1-->3)-D-linked glucose, sizofiran (SPG), schizophyllan, mannan, lentinan, Su-polysaccharide (Su-Ps) and mannozym" can be found throughout the application and, *inter alia*, in the original claims 45 and 46 and at page 39, line 29 through page 30, line 11 of the present specification. Claims 53, 57 and 71 are amended to conform with the previous amendment of claim 36. Claims 72 and 79 are amended to overcome certain rejections. The above-described amendments do not introduce any new matter into the present application.

Withdrawn rejections and objections

Applicant appreciates the Examiner's withdraw of rejections and objection as set forth in Paper No. 13 that are not repeated in the present Office Action (Paper No. 16).

Priority

The present application claims priority benefit of U.S. Provisional Patent Application Serial No. 60/177,024, filed January 19, 2000, under 35 U.S.C. § 119(e). The priority claim is referenced at page 1, lines 2-5 of the present specification and in the Declaration of the Inventor in response to the Notice to File Missing Parts submitted on August 2, 2001 (Exhibit A). Therefore, applicant fully complies with 35 U.S.C. § 119(e). Applicant requests that the Examiner acknowledges the priority claim under 35 U.S.C. § 119(e) in the next Office communication.

Rejections under 35 U.S.C. § 112

Claim 72 is rejected under 35 U.S.C. 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner states that claim 72 recites “buccal” as a type of neoplasm to be treated. The Examiner alleges that it is unclear what the metes and bounds of the claim encompasses as “bruccal” is not a known tissue type or organ. The Examiner further states that for purpose of examination, bruccal will be read as “buccal”.

This rejection is overcome by the replacement of “bruccal” with “buccal” in claim 72.

Claim 79 is rejected under 35 U.S.C. 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, Examiner alleges that claim 79 recites is indefinite for reciting “cytolytic gene sequence”.

This rejection is overcome by the deletion of “cytolytic gene sequence” in claim 79.

Claim 79 is rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to comply with the written description requirement. Specifically, Examiner alleges that claim 79 lacks written description for reciting “cytolytic gene sequence”.

This rejection is overcome by the deletion of “cytolytic gene sequence” in claim 79.

Claim 79 is are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods comprising the administration of a cytokine containing depot, does not allegedly provide enablement for methods comprising the administration of a suicide gene sequence, a cytolytic gene sequence, a cytokine gene sequence, a reporter, a reporter gene sequence or a radiation sensitizer.

This rejection is overcome by the deletion of “a suicide gene sequence, a cytolytic gene sequence, a cytokine gene sequence, a radiation sensitizer” and “a reporter and a reporter gene sequence” in claim 79.

Claim 72 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods for treating neoplasms consisting of adrenal gland, anus, bile ducts, bladder, bone, breast, b[r]uccal, cervix, colon, ear, endometrium, esophagus, eyelids, fallopian tube, gastrointestinal tract, head and neck, heart, kidney, larynx, liver, lung, mandible, mandibular condyle, maxilla, mouth, nasopharynx, nose, oral cavity, ovary, pancreas, parotid gland, penis, pinna, pituitary, prostate gland, rectum, salivary glands, skin, small intestine, stomach, testes, thyroid, tonsil, urethra, uterus, vagina and vulva neoplasm does not allegedly provide enablement for methods of treating neoplasms consisting of auditory nerve, brain, central nervous system, eye, spinal cord and vestibulocochlear nerve.

This rejection is overcome by the deletion of auditory nerve, brain, central nervous system, eye, spinal cord and vestibulocochlear nerve in claim 72.

Claim 44 is rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to comply with the written description requirement. Specifically, Examiner alleges that claim 79 lacks written description for reciting “an enzyme, a non-virulent virus, a polysaccharide and a herb extract.”

This rejection is overcome by the amendment of claim 44.

Claims 53 and 57 are objected to as being dependent upon a canceled base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

These objections are overcome by the amendments of claim 53 and 57.

CONCLUSION

Applicant submits that the rejections of claims 44, 72 and 79 under 35 U.S.C. § 112 and objections to claims 53 and 57 have been overcome by the above remarks and/or amendments. Early allowance of the pending claims 36, 37, 39, 40, 42-44, 47, 48, 50, 53, 57, 69, 71-77 and 79 are earnestly requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 494492000100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 6, 2004

Respectfully submitted,

By 

Peng Chen

Registration No.: 43,543
MORRISON & FOERSTER LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130
(858) 720-5117



RECEIVED
JAN 12 2004
TECH CENTER 1550/2300

Docket No.: 494492000100	Atty: Peng Chen <i>AKB</i>
Serial No.: 09/765,060	Filing Date: January 17, 2001
Title: COMBINATIONS AND METHODS FOR TREATING NEOPLASMS	
Date of Mailing: AUGUST 2, 2001 VIA FIRST CLASS MAIL	


Papers enclosed:

1. Transmittal Form - 1 page
2. Fee Transmittal - 1 page (in duplicate)
3. Petition for 1 Mo Extension, 1 page (in duplicate)
4. Copy of Notice to File Missing Parts of Application - 2 pages
5. Declaration for Utility Patent Application (executed) - 3 pgs
6. Drawings Transmittal, 1 page
7. Drawings, 3 pages
8. Return Postcard

AKB



RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE



Please type a plus sign (+) inside this box

PTO/SB/21 (08-00)
Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

14

Application Number	09/765,060
Filing Date	January 17, 2001
First Named Inventor	Baofa YU
Group Art Unit	1646
Examiner Name	To be assigned
Attorney Docket No.	494492000100

RECEIVED
JAN 12 2004
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

- | | | |
|---|---|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers (for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input checked="" type="checkbox"/> Drawing(s), 3 sheets | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input checked="" type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input checked="" type="checkbox"/> 1 Mos. Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Notice to File Missing Parts;
Drawings Transmittal;
Return Postcard |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/ Incomplete Application | | |
| <input checked="" type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

Remarks



25225

PATENT TRADEMARK OFFICE

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Peng Chen
Signature	
Date	August 2, 2001

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on August 2, 2001.

Rhea Amid

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
FOR FY 2001

JAN 08 2004

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$1,006.00)

Attorney Docket No.

494492000100

Complete if Known

Application Number	09/765,060
Filing Date	JANUARY 17, 2001
First Named Inventor	Baofa YU
Examiner Name	(not yet assigned)
Group Art Unit	1646

RECEIVED
JAN 12 2004
TECH CENTER 1600/2900**METHOD OF PAYMENT**

- 1.
- ☒
- The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit
Account
Number

03-1952, ref. 494492000100

Deposit
Account
Name

Morrison & Foerster LLP

- ☒
- Charge Any Additional Fee Required
-
- Under 37 CFR 1.16 and 1.17
-
- Applicant claims small entity status.
-
- See 37 CFR 1.27

- 2.
- ☐
- Payment Enclosed:

☐ Check ☐ Credit Card ☐ Money Order ☐ Other**FEE CALCULATION****1. BASIC FILING FEE**

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	355
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$355)

2. EXTRA CLAIM FEES

Total Claims	79	20 =	Extra Claims	59	x	Fee from below	9	=	Fee Paid
Independent Claims	2	3 =	0	x					\$-0-

Multiple Dependent

= \$

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
103	18	203	9	Claims in excess of 20	
102	80	202	40	Independent claims in excess of 3	
104	270	204	135	Multiple dependent claims, if not paid	
109	80	209	40	**Reissue independent claims over original patent	
110	18	210	9	**Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$531)

** or number previously paid, if greater; For reissues, see above.

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	65
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	55
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions of the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per properties (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$120.00)

SUBMITTED BY

Name (Print/Type)

Peng Chen

Registration No.
(Attorney/Agent)

43,543

Complete (if applicable)

Telephone

(858) 720-5117

Signature

Date

AUGUST 2, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)

Docket Number.
494492000100In re Application of
Baofa YU

Application Number

09/765,060

Filed

1/17/2004

For

**COMBINATIONS AND METHODS FOR TREATING
NEOPLASMS**Group Art Unit
1646Examiner
To be assignedRECEIVED
JAN 12 2004
TECH CENTER 1600/2300

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

- ☒ One month (37 CFR 1.17(a)(1)) \$ 55.00
- ☐ Two months (37 CFR 1.17(a)(2)) \$ _____
- ☐ Three months (37 CFR 1.17(a)(3)) \$ _____
- ☐ Four months (37 CFR 1.17(a)(4)) \$ _____
- ☐ Five months (37 CFR 1.17(a)(5)) \$ _____

- ☒ Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$55.
- ☐ A check in the amount of the fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☐ The Commissioner is authorized to charge the above fees to Deposit Account Number 03-1952.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 03-1952, ref. docket no. 494492000100. I have enclosed a duplicate copy of this sheet.

I am the ☐ applicant/inventor
☐ assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ attorney or agent of record.
☐ attorney or agent under 37 CFR 1.34(a).
Registration number if acting under 37 CFR 1.34(a) 44,461.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Aug. 2, 2004
Date


Peng Chen
Signature

PENG CHEN (Reg. No. 43,543)

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of _____ forms are submitted.

Burden Hour Statement. This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.




UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/765,060	01/17/2001	Baofa Yu	494492000100

CONFIRMATION NO. 7710

FORMALITIES LETTER



OC000000006032622

 Peng Chen
 Morrison & Foerster LLP
 Suite 500
 3811 Valley Centre Drive
 San Diego, CA 92130-2332

 RECEIVED
 JAN 12 2004
 TECH CENTER 1600/1000
 Date Mailed: 05/02/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 355 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$531.
 - \$531 for 59 total claims over 20.
- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 951.**

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT
Docket No. 494492000100

COMBINED DECLARATION AND POWER OF ATTORNEY FOR UTILITY PATENT
APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: COMBINATIONS AND METHODS FOR TREATING NEOPLASMS, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on January 17, 2001, as United States Application Serial No. 09/765,060.

I HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
*			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/177,024	Jan. 19, 2000

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to

patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status
*		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

I hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Laurie A. Axford (Reg No. 35,053)	Sanjay S. Bagade (Reg No. 42,280)
Joseph Barrera (Reg No. 44,522)	Erwin J. Basinski (Reg No. 34,773)
Shantanu Basu (Reg No. 43,318)	Richard R. Batt (Reg No. 43,485)
Frank P. Becking (Reg No. 42,309)	Vincent J. Belusko (Reg No. 30,820)
Jonathan Bockman (Reg No. 45,640)	Kimberly A. Bolin (Reg No. 44,546)
Barry E. Bretschneider (Reg No. 28,055)	Tyler S. Brown (Reg No. 36,465)
Nicholas Buffinger (Reg No. 39,124)	A. Randall Camacho (Reg No. 46,595)
Mark R. Carter (Reg No. 39,131)	Robert K. Cerpa (Reg No. 39,933)
Peng Chen (Reg No. 43,543)	Thomas Chuang (Reg No. P-44,616)
Thomas E. Ciotti (Reg No. 21,013)	Cara M. Coburn (Reg No. 46,631)
Matthew M. D'Amore (Reg No. 42,457)	Raj S. Davé (Reg No. 42,465)
Peter Davis (Reg No. 36,119)	Stephen C. Durant (Reg No. 31,506)
Carolyn A. Favorito (Reg No. 39,183)	David L. Fehrman (Reg No. 28,600)
Hector Gallegos (Reg No. 40,614)	Debra J. Glaister (Reg No. 33,888)
Kenneth R. Glick (Reg No. 28,612)	Johney U. Han (Reg No. 45,565)
Douglas G. Hodder (Reg No. 41,840)	Charles D. Holland (Reg No. 35,196)
Peter Hsieh (Reg No. P-44,780)	Wayne Jaeschke, Jr. (Reg No. 38,503)
Madeline I. Johnston (Reg No. 36,174)	Richard D. Jordan (Reg No. 33,519)
Parisa Jorjani (Reg No. 46,813)	Ararat Kapouytian (Reg No. 40,044)
Richard C. Kim (Reg No. 40,046)	Cameron A. King (Reg No. 41,897)
Kawai Lau (Reg No. 44,461)	Rimas T. Lukas (Reg No. 46,451)
Lisa E. Marks (Reg No. 44,901)	Michael J. Mauriel (Reg No. 44,226)
Gladys H. Monroy (Reg No. 32,430)	Philip A. Morin (Reg No. P-45,926)
Kate H. Murashige (Reg No. 29,959)	Martin M. Noonan (Reg No. 44,264)
Irene T. Pleasure (Reg No. 45,506)	Catherine M. Polizzi (Reg No. 40,130)
Paul J. Riley (Reg No. 38,596)	Robert Saltzberg (Reg No. 36,910)
Debra A. Shetka (Reg No. 33,309)	Terri Shieh-Newton (Reg No. 47,081)
Rebecca Shortle (Reg No. 47,083)	Kevin R. Spivak (Reg No. 43,148)
Stanley H. Thompson (Reg No. 45,160)	Michael R. Ward (Reg No. 38,651)
E. Thomas Wheelock (Reg No. 28,825)	Todd W. Wight (Reg No. 45,218)
Thomas G. Wiseman (Reg No. 35,046)	Frank Wu (Reg No. 41,386)
David T. Yang (Reg No. 44,415)	Peter J. Yim (Reg No. 44,417)
George C. Yu (Reg No. 44,418)	Karen R. Zachow (Reg No. 46,332)

and:

Please direct all communications to:


Peng Chen
Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332

Please direct all telephone calls to Peng Chen at (858) 720-5117.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


06/21/01
Date

Baofa Yu
Name: Baofa Yu
Residence: San Diego, California 92122 USA
Citizenship: People's Republic of China
Post Office Address: 4443 Governor Drive, San Diego, California 92122 USA



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on AUGUST 2, 2001.


RHEA AMID

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Baofa YU

Serial No.: 09/765,060

Filing Date: JANUARY 17, 2001

For: COMBINATIONS AND METHODS
FOR TREATING NEOPLASMS

Examiner: To Be Assigned

Group Art Unit: 1646

RECEIVED
JAN 12 2004
TECH CENTER 1000/1300

SUBMISSION OF FORMAL DRAWINGS

Assistant Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

Enclosed are THREE (3) sheet(s) of formal drawings in connection with the above-identified application.

Respectfully submitted,

Dated: August 2, 2001

By:


Peng Chen
Registration No. (43,543)

Morrison & Foerster LLP
3811 Valley Centre Dr.
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125





FIG. 1




2/3

RECEIVED
JAN 14 2004
TECH CENTER 1000/1300


SPINAL NEEDLE




SLOWLY INJECTION




TURNING THE TOP OF
NEEDLE, AROUND IN TUMOR



PREPARATION OF INJECTION
CHANNELS IN TUMOR BY THE
PROBE OF INJECTOR



MULTIPLE INJECTION AT ONE
TIME PERIOD INJECTION AT
DIFFERENT TIME



HIGH PRESSURE INJECTION BY
DILOTON INJECTOR 0-6. AMP AT
ONE TIME. HIGH PRESSURE
SOLUTION CAN PENETRATE INTO
AN EXTRACELLULAR MATRIX
BETWEEN TUMOR CELLS

FIG. 2



3/3

RECEIVED
JAN 12 2004
TECH C




FIG. 3




FIG. 4